Company intelligence / Profile preview

PB Immune Therapeutics

Seoul, South Koreapbimmunetherapeutics.com ↗

Ownership: Private
Development stage: Other

Overview

All identified assets are in preclinical or discovery stage; no clinical results in humans have been reported as of May 2025. Their platform enables the generation of endogenous and CAR-modified regulatory T cells (Tregs) for targeted immunomodulation in autoimmune diseases. Some assets (e.g., PB201) emphasize a proprietary GMP-grade proliferation process for Tregs with high expansion efficiency.

Therapeutic areas: OncologyImmunologyNeurology
Modalities: Tregs cell therapyCAR-TregAntibody fusion proteinsExosomesMonoclonal antibody
Industry: Biotech

Drug pipeline

5 assets

PB 20X

Preclinical

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on PB Immune Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PB Immune Therapeutics.

Explore the full profile